Tag Archives: Recordati

Novartis offloads lagging endocrine drugs to Recordati for $390M

Novartis has been busy doing M&A to focus on higher-margin, innovative medicines under CEO Vas Narasimhan. Toward that goal, the Swiss drugmaker has taken another step and offloaded three endocrine drugs to Recordati. The drugs on the chopping board are Signifor, its long-acting sister Signifor LAR and in-development follow-up osilodrostat (LCI699). For the three of them,… Read More »